Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oligonucleotide based RNA base editing therapeutics - Edigene

Drug Profile

Research programme: oligonucleotide based RNA base editing therapeutics - Edigene

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EdiGene Inc
  • Class Antineoplastics; Eye disorder therapies; Oligonucleotides
  • Mechanism of Action Iduronidase stimulants; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Eye disorders; Musculoskeletal disorders; Neurological disorders
  • No development reported Mucopolysaccharidosis I

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-I in China (Parenteral)
  • 08 Nov 2022 Early research in Eye disorders in China (Parenteral), prior to November 2022
  • 09 Nov 2021 EdiGene enters into a research collaboration with the University of Wisconsin–Madison for the development of LEAPER™ RNA editing technology into in vivo therapies
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top